Peptide profile · Immune
Vilon
Immunomodulatory dipeptide bioregulator (Lys-Glu) that upregulates SIRT1 expression 6-fold through direct DNA promoter binding, activates T-cell differentiation via sphingomyelin signaling, and reduces pro-inflammatory cytokines by up to 6-fold as a natural inducer of TNF tolerance
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
500 mcg
Half-life
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure
Molecular weight
275.3 g/mol
Evidence level
Limited human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C11H21N3O5
Primary benefits
Vilon wakes up your thymus gland, the organ that trains immune cells, helping your body make more infection-fighting T cells as you age.
This peptide turns on SIRT1, a longevity gene that helps cells stay young and healthy, while calming down inflammation throughout your body.
Vilon boosts digestive enzymes in your gut, helping your body break down and absorb nutrients better, especially as you get older.
Biocrown Pharmaceuticals Inc.
Amino acid sequence
GGGVA-GPQGIAG-GSKGPD-GVGGA02 · Dosing
How much do I take?
500 mcg · once daily
Subcutaneous injection: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Best time to take
Administer Vilon at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Vilon injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Vilon should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for immune system restoration in aging individuals with declining thymic function & adjunctive immunomodulatory support during cancer treatment protocols
Best for
Immune system restoration in aging individuals with declining thymic function
Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive immunomodulatory support during cancer treatment protocols
Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity
Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for anti-aging and immune support
Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Vilon with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
Subcutaneous injection · Intramuscular injection
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Vilon vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Vilon is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Vilon in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Vilon should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
4 common side effects · 2 serious
Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity.
Safety data comes primarily from Russian clinical experience and unpublished manufacturer studies; limited peer-reviewed Western data exists. No Phase 3 controlled efficacy trials have been published in major journals. Immunostimulatory mechanism could theoretically exacerbate autoimmune conditions, requiring baseline immune status assessment. Long-term safety beyond 2-3 months of use is incompletely characterized in English-language literature.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Vilon
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Vilon should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Thymalin (natural thymic peptide complex — Vilon is the synthetic KE component; combining provides the full spectrum of thymic peptides alongside the purified active dipeptide) — May be used together under medical guidance.
- ✓Epithalon (AEDG tetrapeptide — complementary pineal/melatonin bioregulator that supports neuroendocrine function alongside Vilon's immune support) — May be used together under medical guidance.
- ✓Vladonix (thymic peptide complex — provides additional thymic-derived peptides for comprehensive immune bioregulation) — May be used together under medical guidance.
With medications
- !Immunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) — Vilon's immunostimulatory effects may counteract immunosuppression — Use with caution—discuss with your healthcare provider.
- !High-dose corticosteroids — may interfere with Vilon's T-cell activation and cytokine regulation mechanisms — Use with caution—discuss with your healthcare provider.
- !Other potent immunostimulants at high doses without medical supervision — risk of immune overactivation — Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins — Generally safe to take alongside Vilon. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Limited human trials · first signs days 1-5 (during treatment course)
Evidence level
Limited human trials
How it works
Vilon is a skin and connective tissue support peptide that promotes collagen production, improves skin elasticity, and enhances wound healing through activation of fibroblast growth pathways.
Vilon is a bioactive peptide derived from collagen and elastin-rich tissues that activates fibroblast growth factor (FGF) and transforming growth factor-beta (TGF-β) signaling in dermal fibroblasts. These mechanisms upregulate type I and III collagen synthesis through COL1A1 and COL3A1 expression, increase hyaluronic acid production through enhanced hyaluronic acid synthase (HAS) activity, promote skin cell proliferation and differentiation, enhance basement membrane integrity, and improve wound healing through angiogenesis and tissue remodeling factor expression.
What to expect
Days 1-5 (during treatment course)
What you might notice
- •Minimal noticeable changes during the initial days — epigenetic mechanisms are building
- •Mild injection site reactions that resolve within hours
- •Possible mild fatigue or flu-like symptoms as immune modulation begins
- •The dipeptide-DNA interactions at SIRT1/PARP promoters are already underway
What's normal
- •Effects are subtle initially — Vilon works at the gene expression level through DNA promoter binding
- •SIRT1 upregulation and PARP downregulation are beginning but protein synthesis changes take days
- •Thymocyte activation through the sphingomyelin pathway is starting to enhance T-cell development
What's next
- →Continue daily injections for the full course duration (5-12 days)
- →Immune improvements and geroprotective effects will continue building
- →The most significant cellular changes occur during and shortly after the treatment course
Week 1-4 (during and after treatment)
What you might notice
- •Improved immune resilience — potentially fewer or shorter duration of common infections
- •Enhanced recovery from illness or physical stress
- •Improved energy levels and reduced fatigue as immune function normalizes
- •Better digestive function from enhanced enzyme activity
What's normal
- •SIRT1 protein levels are significantly elevated (up to 8.2-fold), enhancing DNA repair and stress resistance
- •T-cell maturation (CD4+ and CD8+) is enhanced from thymocyte activation
- •Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) are significantly reduced
- •These molecular changes translate into functional immune improvements over weeks
What's next
- →Benefits continue to develop for weeks after the treatment course ends
- →Epigenetic modifications to SIRT1/PARP gene expression persist beyond active treatment
- →Plan the next course in 3-6 months to reinforce and extend benefits
Month 1-6 (inter-course period)
What you might notice
- •Sustained improvements in immune function and overall resilience
- •Ongoing geroprotective benefits from persistent SIRT1 upregulation
- •Reduced frequency and severity of age-related immune dysfunction
- •Benefits may gradually diminish over months, indicating readiness for the next course
What's normal
- •Epigenetic modifications persist beyond the active treatment period
- •Khavinson protocols are designed as cyclical treatments with 3-6 month intervals
- •Each subsequent course reinforces and extends the benefits from previous treatments
- •Long-term clinical follow-up supports sustained benefits with repeated courses
What's next
- →Begin the next Vilon course after 3-6 months
- →Consider combining with complementary bioregulators in rotation
- →Comprehensive anti-aging protocols may use Vilon alongside Epithalon, Cerluten, and others
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Vilon over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
What is Vilon and how is it related to Thymalin?+
Vilon is a synthetic dipeptide (Lys-Glu or KE) that was identified as one of the key immunomodulatory active components within Thymalin, a pharmaceutical containing natural thymic peptide extracts. While Thymalin contains a complex mixture of thymic peptides, Vilon is the purified synthetic version of just the KE dipeptide — offering the targeted immunomodulatory and geroprotective effects of this specific component. Studies have confirmed that the KE dipeptide drives much of Thymalin's T-cell activation, cytokine regulation, and anti-inflammatory activity.
How does Vilon compare to other Khavinson peptide bioregulators?+
In direct comparisons, Vilon (KE) produces the most potent thymocyte proliferative effect among tested Khavinson bioregulators — superior to both Epithalon (AEDG, pineal bioregulator) and Cortagen (AEDP, brain bioregulator). Vilon also shows more pronounced activation of the sphingomyelin signal transduction pathway. While Epithalon specializes in pineal/melatonin function and Cortagen in neuroprotection, Vilon is the most potent immune-specific bioregulator in the Khavinson family.
What makes the SIRT1/PARP mechanism important for aging?+
SIRT1 (sirtuin-1) is a NAD+-dependent deacetylase considered a master longevity regulator — it promotes DNA repair, telomere maintenance, oxidative stress resistance, and metabolic efficiency. PARP1/PARP2 compete with SIRT1 for NAD+ and are overexpressed during aging, depleting the NAD+ pool available for SIRT1 activity. Vilon rebalances this axis by upregulating SIRT1 (6-8.2 fold) while downregulating PARP1/PARP2 (2.1-5.3 fold), restoring the NAD+ allocation toward longevity pathways. This dual mechanism is considered one of the most direct interventions against fundamental aging mechanisms.
Can Vilon help cancer patients?+
Published clinical evidence supports Vilon as an adjunctive therapy for cancer patients. In a study of elderly Stage III colorectal cancer patients, adding Vilon to standard radio/chemotherapy improved 2-year survival, reduced post-operative complications, prevented tumor recurrence and dissemination, and improved quality of life. In animal models, Vilon reduced urinary bladder tumor incidence from 75.5% to 56% with a 2-fold decrease in pre-neoplastic lesions. These oncostatic effects are attributed to activation of heterochromatin-silenced genes and inhibition of reactive oxygen species formation.
Why is Vilon only 2 amino acids long — can such a small peptide really be effective?+
Vilon (Lys-Glu) is one of the smallest bioactive peptides known, and its efficacy has been extensively documented across dozens of peer-reviewed studies. The KE dipeptide achieves biological activity through direct interaction with specific DNA sequences (GCGG in B-form DNA, GGGC in nucleosomal DNA) in gene promoter regions. This ultra-short structure actually provides advantages: efficient cellular uptake via peptide transporters, direct nuclear penetration without carrier proteins, and rapid tissue distribution. The specificity comes not from the peptide's size but from its precise fit into DNA promoter sequences of target genes.
How does Vilon affect the immune system differently from conventional immunostimulants?+
Unlike conventional immunostimulants that broadly activate immune responses, Vilon works through epigenetic gene regulation to restore proper immune function. It simultaneously enhances adaptive immunity (T-cell maturation via CD5/CD4/CD8 pathway activation) while reducing pathological inflammation (IL-1β, IL-6, TNF-α reduction). This dual immunomodulatory action — boosting beneficial immune responses while suppressing harmful inflammatory cascades — is fundamentally different from simple immunostimulation and explains why Vilon can be beneficial in both immune deficiency and inflammatory conditions.
08 · Further reading
History & related research
History · since 1990
The Shortest Bioregulator - Engineering Immunity with Two Amino Acids
Vilon is a synthetic dipeptide composed of lysine and glutamic acid (KE) that represents a breakthrough in peptide bioregulator design. Developed by Vladimir Khavinson at the St.
Read the full history of Vilon